Highlights

  • AbbVie reported Q1FY25 net sales of USD 13,343 million, up 8.4% year-over-year
  • Net income declined 6.3% YoY to USD 1,286 million due to higher operating and other expenses
  • AbbVie has entered a collaboration with ADARx Pharmaceuticals to develop next-gen siRNA therapies
  • Full-year 2025 EPS guidance was raised to USD 12.09–12.29, factoring in Q1 IPR&D expenses

AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical company. It focuses on research and development. The company also manufactures, markets, and sells medicines and therapies.

In the first quarter of the financial year 2025 (Q1FY25), AbbVie reported net sales of USD 13,343 million, marking an 8.4% year-over-year increase compared to USD 12,310 million in Q1FY24. This growth was primarily driven by better performance in its immunology and neuroscience portfolios, which saw increases of 16.6% and 16.1%, respectively.

However, despite the revenue growth, net income declined by 6.3% YoY to USD 1,286 million, largely due to higher total operating costs and other expenses that weighed on profitability.

Operating cash flow also saw a significant drop of 59.5% YoY to USD 1,635 million from USD 4,040 million. This was mainly attributed to lower net income and unfavourable changes in net working capital. As a result, the company’s cash and cash equivalents at the end of Q1FY25 stood at USD 5,175 million, down 6.3% from USD 5,524 million in Q1FY24. This decline reflects cash outflows from both investing and financing activities, though these were partially offset by inflows from operating activities.

Recent Business Update

On May 14, 2025, AbbVie announced a collaboration and license option agreement with ADARx Pharmaceuticals to develop next-generation siRNA therapies. The partnership leverages ADARx’s proprietary RNA technology for targeted mRNA silencing in neuroscience, immunology, and oncology applications.

Company Outlook

AbbVie has raised its full-year 2025 adjusted diluted EPS guidance from USD 11.99–12.19 to USD 12.09–12.29. This updated outlook includes a negative impact of USD 0.13 per share from acquired IPR&D and milestone expenses recorded in Q1. However, it excludes any future IPR&D and milestone costs beyond Q1.

Top 10 Shareholders

AbbVie’s top 10 shareholders collectively hold approximately 30.94% of the company’s total shares, reflecting a diverse ownership base. The Vanguard Group, Inc. holds the largest stake, at 9.80%, and BlackRock Institutional Trust Company, N.A. holds 5.15%, making them the company’s leading shareholders.

Stock Information

The stock price of ABBV has declined by around 6.22% in the past month, whereas it has appreciated by around 2.38% in the past six months. The stock’s 52-week low and high span from USD 153.58 to USD 218.66. As of May 30, the stock’s closing price is USD 186.11.

Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is May 30, 2025. The reference data in this report has been partly sourced from EODHD/Others.

 Technical Indicators Defined

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.